Issue 73, 2020

Fatty acid-like Pt(iv) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36

Abstract

Resistance to the platinum-based chemotherapy drug, cisplatin, is a significant setback in ovarian cancer. We engineered fatty acid-like Pt(IV) prodrugs that harness the fatty acid transporter CD36 to facilitate their entry to ovarian cancer cells. We show that these novel constructs effectively kill cisplatin-resistant ovarian cancer cells.

Graphical abstract: Fatty acid-like Pt(iv) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36

Supplementary files

Article information

Article type
Communication
Submitted
24 Mar 2020
Accepted
05 Aug 2020
First published
05 Aug 2020

Chem. Commun., 2020,56, 10706-10709

Author version available

Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36

A. M. D. S. Jayawardhana, M. Stilgenbauer, P. Datta, Z. Qiu, S. Mckenzie, H. Wang, D. Bowers, M. Kurokawa and Y. Zheng, Chem. Commun., 2020, 56, 10706 DOI: 10.1039/D0CC02174A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements